RF – OX40: A Promising Therapeutic Target in Moderate-to-severe Atopic Dermatitis M. Zulaika-Lloret, M. Rodriguez-Troncoso, R. Ruiz-Villaverde

Facial Vitiligo After SARS-CoV-2 Vaccination M.Á. Flores-Terry, M. García-Arpa, J.L. Santiago-Sánchez Mateo, G. Romero Aguilera

Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria: Subanalysis of AEDV EQUIDAD and AME Projects M. Sánchez-Díaz, Á. Flórez, G. Carretero-Hernández, M. Grau-Pérez, I. García-Doval, J.M. Carrascosa-Carrillo